This is because GLP-1 receptor agonists like Ozempic can suppress appetite and increase feelings of fullness, leading to reduced calorie intake
Here is the foundational math
In contrast, only 27% of those on placebo saw a weight reduction of at least 5%
doi: 10.1111/1753-0407.12891 Summary Keywords diabetic kidney disease, diabetic nephropathy, GLP-1 receptor agonists, liraglutide, semaglutide, dulaglutide Citation Kawanami D and Takashi Y (2020) GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms
Theres also the problem of user error
The different roles of V-ATPase a subunits in phagocytosis/endocytosis and autophagy, Autophagy (2024) 117, Zhang J, Zeng W, Han Y, et al